- Strategic awareness initiatives underway ahead of IzoView commercialization -
- Company podcast and breasct.com website in development to expand engagement -
- Market-facing activities aligned with investor communications and corporate milestones -
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - July 15, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it is initiating strategic awareness plans in anticipation of the future commercialization of its breakthrough device, the IzoView Breast CT Imaging System.
Izotropic's awareness efforts will center on a consistent and compelling stream of development-related news to educate global audiences on the transformative value of dedicated breast CT technology. These initiatives will spotlight how IzoView stands apart from traditional breast imaging modalities and competing breast CT systems, positioning it as a true game-changer in the field. The campaign will emphasize IzoView's unique, proprietary features including patented hardware innovations, trade-secret software elements, and next-generation AI integrations, to reinforce the device's competitive edge and accelerate market adoption. Emerging breast imaging trends, evolving regulatory frameworks, and robust market growth forecasts will be incorporated to contextualize IzoView's potential. The Company's narrative will be refined, data-driven, and strategically repackaged to engage new audiences and support its commercialization and go-to-market initiatives.
To complement these efforts and broaden reach while building on a growing stream of corporate developments, Izotropic will launch a new podcast series focused on discussing Company news and key milestones as they unfold. The podcast will deliver clear and timely commentary on Izotropic's corporate updates, providing context around press releases, clinical milestones, regulatory progress, and strategic initiatives, while highlighting relevant developments across the breast imaging and medical technology sectors to help listeners stay current on the trends shaping the commercial landscape. Designed to be concise and informative, the podcast will serve as a consistent communication channel for stakeholders, offering accessible insights as the Company advances toward market launch.
Supporting both the awareness campaign and podcast series, Izotropic will also introduce breastct.com. This dedicated online platform will initially feature articles about breast CT technology, the Company's progress, and the unique advantages of IzoView. The site is developed to evolve over time into a comprehensive educational resource, supporting patient awareness and engagement as Izotropic moves through regulatory processes in the U.S. and Europe. Overtime, breastct.com will serve as a centralized destination for patients, clinicians, and advocates seeking accessible, trusted information about IzoView and the evolving role of breast CT in cancer detection and care.
These efforts form part of a broader, coordinated awareness strategy developed in collaboration with Izotropic's capital markets and industry advisory team, with a focus on aligning investor engagement, investor communications, and market-facing activities with its long-term regulatory and commercialization objectives.
About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR+ at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all Forward-Looking Statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258830
SOURCE: Izotropic Corporation
